var data={"title":"Timolol (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Timolol (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=timolol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Timolol (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600170\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of ischemic heart disease following abrupt withdrawal:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered timolol, particularly in patients with ischemic heart disease, gradually reduce the dosage over a period of one to two weeks and carefully monitor the patient. If angina markedly worsens or acute coronary insufficiency develops, reinstitute timolol administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients against interruption of discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue timolol therapy abruptly, even in patients treated only for hypertension.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600485\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Beta-Blocker, Nonselective</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600252\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial: 10 mg twice daily, increase gradually every 7 days, usual dosage: 20 to 40 mg/day in 2 divided doses; maximum: 60 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine prophylaxis:</b> Oral: Initial: 10 mg twice daily, increase to maximum of 30 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myocardial infarction (secondary prevention):</b> Oral: Initial: 5 mg twice daily; may increase to a target dose of 10 mg twice daily (Fonarow 2006; Norwegian Multicenter Study Group 1981). In general, oral beta-blockers should be initiated within the first 24 hours following STEMI (in the absence of contraindications) and continued during and after hospitalization; however, the use of timolol is not routine (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (rate control) (off-label use):</b> Initial: 10 mg twice daily; increase at weekly intervals as tolerated to 20 mg twice daily, then to a maximum of 30 mg twice daily; may use in combination with digoxin (Ribeiro 1986). <b>Note:</b> Timolol is not commonly used for rate control in atrial fibrillation (AHA/ACC/HRS [January 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600253\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22806560\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in manufacturer&rsquo;s labeling. However, timolol is primarily eliminated renally; dosage reduction may be necessary. Significant hypotension has been seen in patients with severe impairment and undergoing dialysis. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22806561\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in manufacturer&rsquo;s labeling. However, timolol is partially metabolized by the liver; dosage reduction may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600285\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as maleate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600178\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600179\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Treatment of hypertension and angina; to reduce mortality following myocardial infarction; prophylaxis of migraine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James, 2013]): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &ge;60 years of age, with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &lt;60 years of age, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull;\t Patients &ge;18 years of age with diabetes, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &ge;18 years of age with chronic kidney disease (CKD), with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">In patients with chronic kidney disease (CKD), regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker <b>instead of</b> an ACEI or ARB. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27254668\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Atrial fibrillation (rate-control)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600173\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Timolol may be confused with atenolol, Tylenol&reg;</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600199\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac failure, cerebral ischemia, cerebrovascular accident, claudication, cold extremities, edema, heart block, hypotension, palpitations, Raynaud's phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Amnesia, anxiety, confusion, depression, disorientation, drowsiness, exacerbation of myasthenia gravis, hallucination, insomnia, nervousness, nightmares, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, exacerbation of psoriasis, pemphigoid-like lesion, psoriasiform eruption, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hypoglycemia (masked)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, Peyronie's disease, retroperitoneal fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharoptosis, cystoid macular edema, decreased corneal sensitivity, diplopia, eye discharge, eye pain, keratitis, visual disturbance (including refractive changes), xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cough, nasal congestion, pulmonary edema, respiratory failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600185\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to timolol or any component of the formulation; sinus bradycardia; sinus node dysfunction; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; bronchospastic disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600197\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; can worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prinzmetal variant angina: Beta-blockers without alpha1-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer, 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; marked hypotension can occur in patients maintained on hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: <b>[US Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.</b> Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600203\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600204\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9945&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Citalopram; Escitalopram; FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600180\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600181\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were not observed in the initial animal reproduction studies. Timolol crosses the placenta (Schneider 1988) and decreased fetal heart rate has been observed following maternal use of timolol during pregnancy (Devoe 1986). Adverse events, such as fetal/neonatal hypoglycemia and reduced birth weight, have been observed following in utero exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth is generally recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are also associated with adverse events in the fetus, infant, and mother (ACOG 2015; Magee 2014). Although beta-blockers may be used when treatment of hypertension in pregnancy is indicated, agents other than timolol are preferred (ACOG 2013; Magee 2014). In addition, other agents are preferred when migraine prophylaxis is needed in pregnant women (Pringsheim 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600184\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Timolol is excreted into breast milk. Based on data obtained following maternal use of ophthalmic timolol, it is recommended that nursing infants (especially those with cardiorespiratory problems) be monitored for adverse events (Madadi 2008). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600254\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be administered with food at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600257\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor heart rate, blood pressure, apical and radial pulses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600221\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptors; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity through an unknown mechanism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600223\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hypotensive: 15 to 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 0.5 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and complete (~90%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 1.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP2D6; extensive first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 2.7 hours; prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (15% to 20% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600287\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Timolol Maleate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $137.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $170.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $314.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390238\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Blocadren (AT, IT, LB, QA);</li>\n      <li>Blocadren Depot (NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devoe LD, O'Dell BE, Castillo RA, et al, &quot;Metastatic Pheochromocytoma in Pregnancy and Fetal Biophysical Assessment After Maternal Administration of Alpha-Adrenergic, Beta-Adrenergic, and Dopamine Antagonists,&quot; <i>Obstet Gynecol</i>, 1986, 68(3 Suppl):15S-18S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/2874538/pubmed\" target=\"_blank\" id=\"2874538\">2874538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16534490\"></a>Fonarow GC. Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. <i>Rev Cardiovasc Med</i>. 2006;7(1):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/16534490/pubmed\" target=\"_blank\" id=\"16534490\">16534490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130:e199-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madadi P, Koren G, Freeman DJ, et al, &quot;Timolol Concentrations in Breast Milk of a Woman Treated for Glaucoma: Calculation of Neonatal Exposure,&quot; <i>J Glaucoma</i>, 2008, 17(4):329-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/18552619/pubmed\" target=\"_blank\" id=\"18552619\">18552619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/9562933/pubmed\" target=\"_blank\" id=\"9562933\">9562933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mundorf TK, Ogawa T, Naka H, et al, &ldquo;A 12-Month, Multicenter, Randomized, Double-Masked, Parallel-Group Comparison of Timolol-LA Once Daily and Timolol Maleate Ophthalmic Solution Twice Daily in the Treatment of Adults With Glaucoma or Ocular Hypertension,&rdquo; <i>Clin Ther</i>, 2004, 26(4):541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/15189751/pubmed\" target=\"_blank\" id=\"15189751\">15189751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7010157\"></a>Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. <i>N Engl J Med</i>. 1981;304(14):801-807.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/7010157/pubmed\" target=\"_blank\" id=\"7010157\">7010157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2 Suppl 2):S1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/22683887 /pubmed\" target=\"_blank\" id=\"22683887 \">22683887 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3548664\"></a>Ribeiro LG, Kasdin SL, Snyder DL, Fisher MB, Irvin JD.l. Beneficial effects of timolol in digitalized patients with atrial fibrillation and a rapid ventricular response. <i>Arq Bras Cardiol</i>. 1986;46(3):211-215.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/3548664/pubmed\" target=\"_blank\" id=\"3548664\">3548664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schneider H and Proegler M, &quot;Placental Transfer of Beta-Adrenergic Antagonists Studied in an <i>in vitro</i> Perfusion System of Human Placental Tissue,&quot; <i>Am J Obstet Gynecol</i>, 1988, 159(1):42-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/2899395/pubmed\" target=\"_blank\" id=\"2899395\">2899395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo; <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Timolol (prescribing information). Mylan PHarmaceuticals, Inc: Morgantown, WV; August 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo; <i>Clin Pharmacokinetics</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-systemic-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9945 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9600170\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9600485\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9600252\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9600253\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22806560\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22806561\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9600285\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9600178\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9600179\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F27254668\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9600173\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9600199\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9600185\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9600197\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9600203\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9600204\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9600180\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9600181\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9600184\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9600254\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9600257\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9600221\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9600223\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9600287\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390238\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9945|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=timolol-systemic-patient-drug-information\" class=\"drug drug_patient\">Timolol (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}